Know Labs (NYSE:KNW) today announced the results of a feasibility study comparing its glucose monitoring technology to the Dexcom G6 CGM. The company titled its study “Technical Feasibility of a Novel Sensor for Non-Invasive Blood Glucose Monitoring Compared to Dexcom G6.” It’s presenting results today at the American Association of Clinical Endocrinology (AACE) Annual Meeting in […]
Clinical Trials
UK study backs Dexcom real-time CGM
Dexcom (Nasdaq:DXCM) announced today that a published study in the UK supports its real-time continuous glucose monitoring (rtCGM). San Diego-based Dexcom published its study in Diabetes Therapy. It’s titled “Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK.” The […]
Fractyl Health initiates global registry for diabetes reversal treatment
Fractyl Health announced that it initiated its Revita Global Registry Program in Germany to study its diabetes reversal treatment. On April 20, the Ethics Committee of the University of Freiburg (Germany) granted clearance for the initiation of a registry study. The study covers the Revita system in German hospitals. Patients in the registry have inadequately […]
Researchers develop wearable patch for painless drug delivery through the skin
Researchers at MIT hope to address the difficulties of transdermal drug delivery through a new wearable patch. The MIT team sees the skin as an appealing route for drug delivery. It enables the drugs to travel directly to the necessary site, which offers benefits in wound care, pain relief and more. However, the tough outer […]
Study supports non-invasive glucose monitoring tech from Know Labs
Know Labs (NYSE:KNW) today announced positive study data supporting its proprietary non-invasive glucose monitoring technology. Seattle-based Know Labs develops its proprietary Bio-RFID technology. It uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. This technology integrates into wearable, mobile or bench-top form factors. Know Labs developed the first […]
Senseonics announces first pediatric 365-day CGM insertion
Senseonics (NYSE:SENS) announced that the first pediatric study participant received an Eversense 365-day CGM insertion. The insertion took place as part of the company’s ENHANCE clinical trial at the AMCR Institute. AMCR, a clinical research center, focuses on pre-diabetes, type 1, type 2 diabetes and obesity. The study operates under the direction of Dr. Timothy […]
Tandem reports positive research for its artificial pancreas tech
Tandem Diabetes Care (Nasdaq:TNDM) today announced a positive meta-analysis of three randomized controlled trials of its Control-IQ advanced hybrid closed-loop technology. The research found immediate and sustained improvements for a diverse range of subjects using Control-IQ technology, according to the research published in the journal Diabetes Technology & Therapeutics. There was an average increase in […]
Study backs self-administration with Vaxxas vaccine patch
Vaxxas today announced clinical trial data demonstrating the potential of its high-density microarray patch (HD-MAP) for vaccine delivery. The company published the data highlighting effective vaccine payload delivery in Human Vaccines & Immunotherapeutics. This counts for both trained professionals and individual self-administration. Vaxxas reported an equivalency of observed human skin response and vaccine delivery potential between […]
Study backs Tandem Control-IQ artificial pancreas in young children
Tandem Diabetes Care (Nasdaq:TNDM) announced positive study data for its artificial pancreas using Control-IQ technology. The study demonstrated improved blood sugar control in children ages 2-6 with type 1 diabetes. It evaluated an artificial pancreas using the Tandem t:slim x2 insulin pump with Control-IQ technology. Results were published in the New England Journal of Medicine. […]
Study supports RenovoRx drug-device combo for treating pancreatic cancer
RenovoRx (Nasdaq:RNXT) today announced promising interim data for its RenovoGem drug-device combination for treating pancreatic cancer. The Tiger-Pac clinical trial investigates RenovoGem as a potential treatment option in locally advanced pancreatic cancer (LAPC). Interim data from the Phase III open-label study suggests a six-month potential improvement in median overall survival with RenovoGem. RenovoGem utilizes the […]